Tuesday | Wednesday | Thursday | Friday | Saturday
THURSDAY, DECEMBER 7, 2017
     
6:45 am - 5:15 pm Registration - Main Lobby  
     
7:00 am - 9:00 am Spotlight on Novel Drugs/Predicting Response for HER2+ Breast Cancer - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Ian Krop, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

Discussants
Predicting Response HER2
Christos Sotiriou, MD, PhD
Institut Jules Bordet
Brussels, BELGIUM

Novel HER2 Drugs
Aleix Prat, MD, PhD
IDIBAPS Hospital Clinic
Barcelona, SPAIN

Other Novel Drugs
Pamela Munster, MD
University of California
San Francisco, CA
 
     
7:00 am - 9:00 am Spotlight on Endocrine Resistance Mediated by CDK4/6, FGFR, and PI3K - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Steffi Oesterreich, PhD
University of Pittsburgh Cancer Institute
Pittsburgh, PA

Discussants:
CDK4/6
Shom Goel, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

FGFR
Gordon B. Mills, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

PI3K
Todd Miller, PhD
Geisel School of Medicine at Dartmouth
Lebanon, NH
 
     
7:00 am - 9:00 am

POSTER SESSION 2 & continental breakfast - Hall 1

 
     
 

Detection/Diagnosis

 
 

Circulating Tumor Cells
Circulating Markers
Diagnostic Pathology

P2-01
P2-02
P2-03

 

Tumor Cell and Molecular Biology

 
 

Epigenetics
Genomics
Tumor Heterogeneity/Molecular Subtypes
Molecular Profiles
Oncogenes/Tumor Suppressor Genes

P2-04
P2-05
P2-06
P2-07
P2-08

  Prognostic and Predictive Factors  
 

Predictive Biomarkers for Targeted Therapies
Biomarkers for Chemotherapy

P2-09
P2-10

  Treatment  
  Radiotherapy
Breast Conservation
P2-11
P2-12
     
  Rescheduled Abstracts P2-13
     
9:00 am - 9:30 am PLENARY LECTURE 2 – Hall 3  
 

Advances in the Understanding of Mutational Signatures in Human Cells
Serena Nik-Zainal, MD, PhD
The Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

 
     
9:30 am - 11:30 am

GENERAL SESSION 3 – Hall 3

 
     
9:30 am

S3-01. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

 
  Gnant M,Steger G, Greil R, Fitzal F, Mlineritsch B, Manfreda D, Tausch C, Balic M, Dubsky P, Moik M, Thaler J, Egle D, Bjelic-Radisic V, Selim U, Exner R, Singer C, Melbinger-Zeinitzer E, Haslbauer F, Stöger H, Helfgott R, Sevelda P,  Trapl H, Wette V, Sölkner L, Jakesz R. Medical University of Vienna, Vienna, Austria; Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Salzburg, Austria; Doctor's Office Manfreda, Klagenfurt, Austria; Ordensklinkum Linz, Linz, Austria; Medical University Graz, Graz, Austria; Wels-Grieskirchen Medical Hospital, Wels, Austria; Medical University Innsbruck, Innsbruck, Austria; Hanusch Hospital, Breast Care Center, Vienna, Austria; Hospital Wolfsberg, Wolfsberg, Austria; Hospital Vöcklabruck, Vöcklabruck, Austria; Hospital Hietzing, Vienna, Austria; General Hospital Baden, Baden, Austria; Breast Center, Doctor´s Office Wette, St. Veit/Glan, Austria; ABCSG, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.  
9:45 am

S3-02. NEO-ORB: A phase II, randomized, double-blind, placebo-controlled study of letrozole with alpelisib or buparlisib for the neoadjuvant treatment of postmenopausal women with HR+, HER2- breast cancer

 
  Mayer IA, Prat A, Egle D, Blau S, Fidalgo JAP, Gnant M, Fasching PA, Colleoni M, Wolff AC, Winer EP, Singer CF, Hurvitz S, Estévez LG, van Dam P, Kummel S, Mundhenke C, Holmes F, Turri S, Charbonnier L, Diaz-Padilla I, Sellami D, Arteaga CL. Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN; Hospital Clinic of Barcelona, Barcelona, Spain; Medical University of Innsbruck, Innsbruck, Austria; University of Washington, Seattle, WA; Hospital Clínico Universitario, CIBERONC, Valencia, Spain; Universitätsklinik für Chirurgie, Wien, Austria; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany; Istituto Europeo di Oncologia, Milan, Italy; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MA; Dana-Farber Cancer Institute, Boston, MA; Private Clinic Döbling, Vienna, Austria; University of California, Los Angeles, CA; Centro Integral Oncológico Clara Campal, Madrid, Spain; Antwerp University Hospital, Edegem, Belgium; Kliniken Essen-Mitte, Essen, Germany; Universitätsklinikum Schleswig-Holstein, Kiel, Germany; Texas Oncology-Houston Memorial City and US Oncology Research Network, Houston, TX; Novartis Pharma S.A.S, Rueil-Malmaison, France; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ.  
10:00 am

S3-03. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT - Randomised EuropeAn Celecoxib Trial)

 
  Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK) , Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield, Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; Zentralklinikum Suhl GmbH, Germany.  
10:15 am

S3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study).

 
  Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, Nyandoto P, Villman KK, Halonen P, Granstam-Björneklett H, Lundgren L, Yachnin J, Turpeenniemi-Hujanen T, Ritchie D, Huttunen T, Neven P, Canney P, Harvey VJ, Kellokumpu-Lehtinen P-L, Lindman H. Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; University Hospitals Leuven, Leuven, Belgium; Turku University Central Hospital, Turku, Finland; Kuopio University Hospital, Kuopio, Finland;  Päijät-Häme Central Hospital, Lahti, Finland; Örebro University Hospital, Örebro, Sweden; Västerås Central Hospital, Västerås, Sweden; Skåne University Hospital, Lund, Sweden; Eskilstuna Hospital, Eskilstuna, Sweden; Oulu University Hospital, Oulu, Finland; 4Pharma, Turku, Finland; Auckland City Hospital, Auckland, New Zealand; Tampere University Hospital, Tampere, Finland; Uppsala University Hospital, Uppsala, Sweden.  
10:30 am

S3-05. Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based paclitaxel followed by anthracycline-cyclosphosphamide for patients with early breast cancer - GBG69

 
  Schneeweiss A, Jackisch C, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Rhiem K, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Gerber B, Furlanetto J, von Minckwitz G, Nekljudova V, Loibl S, Untch M. Universitätsklinikum Heidelberg; Sana Klinikum Offenbach; Elisabeth Krankenhaus Kassel; Universitätsklinkum Essen/Universitätsklinikum Leipzig; Charité Universitätsmedizin Berlin; Universitätsklinikum Schleswig-Holstein; St. Barbara-Klinik Hamm-Hessen; Kliniken Essen Mitte; Uniklinik Köln; Kliniken der Stadt Köln; Universitätsklinikum Erlangen; Onkologische Schwerpunktpraxis Bielefeld; Rotkreuzklinikum München; Marien-Hospital Witten; Universitäts-Frauenklinik Rostock; German Breast Group; Helios Klinikum Berlin-Buch.  
10:45 am

S3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (IX) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

 
  Rugo HS, Barry WT, Moreno-Aspitia A, Lyss A, Huebner L,Mayer EL, Naughton M, Layman RM, Carey LA, Somer RA, Toppmeyer D, Velasco M, Perez EA, Hudis CA, Winer E. University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Alliance Statistics and Data Center, Dana-Farber/Partners CancerCare, Boston, MA; Mayo Clinic, Jacksonville, FL; Heartland Cancer Research NCORP, St. Louis, MO; Alliance Statistics and Data Center, Mayo Clinic, Rochester, NY; Dana-Farber/Partners CancerCare; Washington University School of Medicine; MD Anderson Comprehensive Cancer Center; University of North Carolina; Cooper University Hospital; Rutgers Cancer Institute of New Jersey; Cancer Care Specialist of Central Illinois; Genentech, Inc.; Memorial Sloan Kettering Cancer.  
11:00 am

S3-07. Genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA

 
  Stover DG, Parsons HA, Ha G, Freeman S, Barry B, Guo H, Choudhury A, Gydush G, Reed S, Rhoades J, Rotem D, Hughes ME, Dillon DA, Partridge AH, Wagle N, Krop IE, Getz G, Golub TA, Love JC, Winer EP, Tolaney SM, Lin NU, Adalsteinsson VA. The Ohio State University Comprehensive Cancer Center, Columbus, OH; Dana-Farber Cancer Institute, Boston, MA; Broad Institute of Harvard and MIT, Cambridge, MA; Massachusetts Institute of Technology, Cambridge, MA.  
11:15 am

S3-08. TBD

 
     
11:00 am - 5:00 pm EXHIBITS - Hall 2  
     
11:30 am - 12:00 pm

AACR  Distinguished Lectureship in Breast Cancer Research - Hall 3

 
       Leveraging Preclinical Models of Breast Cancer
Jeffrey M. Rosen, PhD
Baylor College of Medicine
Houston, TX

     
12:00 pm - 1:00 pm  BREAK  
     
1:00 pm - 2:00 pm

CASE DISCUSSION 1 – Stars at Night Ballroom 1&2 - 3rd Level

 
  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Panelists:
Melody Cobleigh, MD
Rush University Medical Center
Chicago, IL

Michael Gnant, MD
Medical University of Vienna
Wien, AUSTRIA

Gaorav Gupta, MD, PhD
University of North Carolina
Chapel Hill, NC

Ghecemy Lopez
USC Cancer Center
Los Angeles, CA

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
 
      

1:00 pm - 2:00 pm BASIC SCIENCE FORUM 2 - Stars at Night Ballroom 3&4 - 3rd Level  
 

Mechanisms of Early Dissemination, Dormancy and Metastasis
Moderator: Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY

Ocogenic and microenvironmental signals driving early dissemination, dormancy and metastasis
Julio A. Aguirre-Ghiso, PhD
Mount Sinai School of Medicine
New York, NY

The perivascular niche protects dormant disseminated tumor cells from therapy
Cyrus M. Ghajar, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA

 
      

1:00 pm - 2:00 pm EDUCATIONAL SESSION - Hemisfair Ballroom 2&3 - 3rd Level  
  Challenges in Advanced/Metastatic Breast Cancer (ABC)
Moderator: Fatima Cardoso, MD
Champalimaud Clinical Centre
Lisbon, PORTUGAL

Introduction: Where there is controversy, let it be guidance
Fatima Cardoso, MD
Champalimaud Clinical Centre
Lisbon, PORTUGAL

Luminal ABC: optimal use of all available options?
Angela M. DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA

Local therapy of limited disease in ABC: what is the evidence?
Seema A. Khan, SM, MB
Northwestern University
Chicago, IL

Novel approaches for selection and monitoring of treatment in advanced and metastatic breast cancer - advantages and limitations
Prof. Dr. Carsten Denkert
Charite Berlin
Berlin, GERMANY

Balancing active treatment and palliative care in ABC patients
Thomas J. Smith, MD
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

 
     
2:15 pm - 3:15 pm MINI-SYMPOSIUM 1 - Hall 3  
 

Molecular Subtypes and Clinical Ramifications of TNBC
Moderator: Tiffany A. Traina, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting DNA repair deficiency in triple negative breast cancers (TNBC) with G-quadruplex stabilisers
Samuel Aparicio, PhD
The University of British Columbia
Vancouver, CANADA

New clinical approaches for TNBC
Melinda Telli, MD
Stanford University School of Medicine
Stanford, CA

 
     
3:15 pm - 5:00 pm

GENERAL SESSION 4 – Hall 3
Moderator: TBD

 
     
3:15 pm

S4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

 
  Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, Boni L, Unger JM, Anderson RA, Mehta K, Minton S, Poggio F, Albain KS, Adamson DJA, Gerber B, Cripps A, Bertelli G, Seiler S, Ceppi M, Partridge AH, Del Mastro L. Institut Jules Bordet, Brussels, Belgium; Cleveland Clinic Foundation, Cleveland, OH; Imperial College, London, United Kingdom; GBG - German Breast Group, Neu-Isenburg, Germany; UCSF - University of California, San Francisco, CA; IRCCS AOU San Martino-IST, Genova, Italy; AOU Careggi and Istituto Toscano Tumori, Florence, Italy; SWOG - Fred Hutchinson Cancer Research Center, Seattle, WA; University of Edinburgh, Edinburgh, United Kingdom; Moffitt Cancer Center, Tampa, FL; Loyola University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL; Tayside Cancer Centre, Ninewells Hospital, Dundee, United Kingdom; University Hospital Rostock, Rostock, Germany; Nexgen Oncology, Dallas, TX; Singleton Hospital, Swansea, United Kingdom; Dana-Farber Cancer Institute, Boston, MA.

Matteo Lambertini, MD is a recipient of a SABCS Clinical Scholar Award.
 
3:30 pm

S4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

 
  Pagani O, Regan MM, Fleming GF, Walley BA, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Goetz MP, Ciruelos EM, Stearns V, Debled M, Martino S, Geyer Jr CE, Pinotti G, Coates AS, Goldhirsch A, Gelber RD, Francis PA. SOFT and TEXT Investigators, International Breast Cancer Study Group, Breast International Group and North American Breast Cancer Group.  
3:45 pm

S4-03. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

 
  Fleming G, Francis PA, Láng I, Ciruelos EM, Bellet M, Bonnefoi HR, Climent MA, Pavesi L, Burstein HJ, Martino S, Davidson NE, Geyer Jr CE, Walley BA, Coleman RE, Kerbrat P, Buchholz S, Ingle JN, Rabaglio-Poretti M, Colleoni M, Regan MM. SOFT Investigators, International Breast Cancer Study Group, Breast International Group, and North American Breast Cancer Group.  
4:00 pm

S4-04. Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)

 
  Hershman DL, Unger JM, Greenlee H, Capodice J, Lew DL, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry L, Crew KD. Columbia University Medical Center, New York, NY; Fred Hutchinson Cancer Research Center, Seattle, WA; Mount Sinai Hospital, New York, NY; Kaiser Permanente Medical Center, Walnut Creek, CA; Spectrum Health Medical Group, Grand Rapids, MI; NCORP of the Carolinas (Greenville Health System), Greenville, SC; St. Luke's Mountain States Tumor Institute, Boise, ID; National Cancer Institute, Bethesda, MD; AIM Specialty Health, Chicago, IL; University of Utah Huntsman Cancer Institute, Salt Lake City, UT.  
4:15 pm  S4-05. TBD  
4:30 pm

S4-06. Cancer risks and response to targeted therapy associated with BRCA2 variants of uncertain significance

 
  Couch FJ, Shimelis H, Hart SN, Moore RM, Thomas A, Lipton GB, Iversen E.  Mayo Clinic, Rochester, MN; Duke University, Durham, NC.  
 4:45 pm S4-07. Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer
 
  Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Gucalp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Tudor IC, Markova D, Barry E, Tarazi J, Stewart R, Winer E, Yardley DA. Dana-Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Memorial Sloan-Kettering Cancer Center, New York, NY; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Fort Meyers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospital, City Campus, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma Inc, Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Medivation, Inc. (Medivation, Inc., was acquired by Pfizer, Inc., in September 2016), San Francisco, CA; Pfizer, Inc., New York, NY; Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN.  
 
 
5:00 pm - 7:00 pm

Spotlight on Endocrine Therapy – Stars at Night Ballroom 1&2 - 3rd Level

Chair: Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Discussants:
Neoadjuvant endocrine therapy
Cynthia Ma, MD, PhD
Washington University
St. Louis, MO

SERDS for metastatic ER+ breast cancer
Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Combination therapy with endocrine agents
Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY

 
     
5:00 pm - 7:00 pm  Spotlight on Immuno Oncology - Stars at Night Ballroom 3&4 - 3rd Level  
  Chair: Leisha A. Emens, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD

Discussants:
Immune Metastatic
Justin Balko, PharmD, PhD
Vanderbilt-Ingram Cancer Center
Nashville, TN

Treatment
Elizabeth A. Mittendorf, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Biology
Leisha A. Emens, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD
 
     
5:00 pm - 7:00 pm POSTER SESSION 3 & reception – Hall 1
     

Detection/Diagnosis

Axillary Staging and Sentinel Nodes
Biopsy Techniques

P3-01
P3-02

     
 

Tumor Cell and Molecular Biology

Genetics - Germline Changes
Genetics - Somatic Changes
Immunology and Preclinical Immunotherapy
New Drugs and Mechanisms
Novel/Emerging Therapeutic Targets


P3-03
P3-04
P3-05
P3-06
P3-07

 
 
 

Prognostic and Predictive Factors

Prognostic Factors - Clinical Testing and Validation

P3-08

     
 

Epidemiology, Risk, and Prevention

Risk Factors and Modeling
Other


P3-09
P3-10
 

Treatment

Advanced Endocrine Therapy
Adjuvant Endocrine Therapy
Neoadjuvant Endocrine Therapy
Toxicities-Management
Other
TIssue and Data Banks
Clinical Trial Design and Management

P3-11
P3-12
P3-13
P3-14
P3-15
P3-16
P3-17



 

Ongoing Clinical Trials 2

Ongoing Trials - Surgery
Ongoing Trials - Conservation Surgery
Ongoing Trials - Radiotherapy
Ongoing Trials - Photodynamic Therapy
Ongoing Trials - Chemotherapy
Ongoing Trials - Metastases
Ongoing Trials - New Agents and Strategies

OT2-01
OT2-02
OT2-03
OT2-04
OT2-05
OT2-06
OT2-07


 
 
 7:30 pm OPEN SATELLITE EVENT presented by Medscape Oncology - Marriott Rivercenter, Salon IJ

The Promise of PARP Inhibitors in Metastatic Breast Cancer: New Data, New Treatments?

For more information and to register for this event, please click on the link below:
http://www.medscape.org/sites/townhall/public/gbrca-mbc
 
     
7:30 pm OPEN SATELLITE EVENT presented by Prime Oncology - Marriott Rivercenter

Hope on the Horizon for Triple Negative Breast Cancer
 
 
Tuesday | Wednesday | Thursday | Friday | Saturday